Brentuximab vedotin is an antibody-drug conjungate (ADC) used for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin acts through targeting tumor cells with CD30 antigen expressed in.
SGN-35; previously cAC10-vcMMAE; SGN 35; SGN35
In an in vitro model mimicking GCT of heterogeneous histology, Brentuximab vedotin abrogates cell viability of CD30-positive GCT27 EC line exerting marked time-dependent antiproliferative and pro-apoptotic activity. CD30-negative JAR cultured alone barely responds to brentuximab vedotin, while in coculture with GCT27 brentuximab vedotin induces clear dose-dependent cytotoxicity. Cellular proliferation and cell death are significantly enhanced in CD30-negative JAR cocultured with CD30-positive GCT27 compared to JAR cultured alone in proof of substantial bystander activity of brentuximab vedotin in CD30-negative GCT.
In vivo brentuximab vedotin promoted tumor regression and prolonged survival of mice bearing previously reported UM-PEL-1 tumors as well as UM-PEL-3 tumors derived from a newly established and characterized Kaposi's sarcoma-associated herpesvirus- and Epstein-Barr virus-positive PEL cell line.
Clinical Trial Information
|NCT Number||Condition Or Disease||Phase||Start Date||Sponsor||Status|
|NCT01940796||Graft-vs-Host Disease||Phase 1||2018-07-26||Massachusetts General Hospital||Terminated (Toxicity)|
|NCT03187210||Lymphoma||Phase 1, Phase 2||2021-08-05||University Hospital Inselspital, Berne||Recruiting|
|NCT02227433||Hodgkin Lymphoma||Phase 2||2020-12-22||Fondazione Italiana Linfomi ONLUS||Completed|
|NCT03222492||Diffuse Cutaneous Systemic Sclerosis||Phase 1,Phase 2||2021-04-12||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|
|NCT03587844||Mycosis Fungoides||Phase 2||2021-11-04||Memorial Sloan Kettering Cancer Center||Recruiting|
the treatment of Hodgkin lymphoma and ALCL
Seattle Genetics; Takeda Pharmaceutical